Self-reported adherence to pharmacotherapy in cancer patients
Keywords:Adherence, Cancer, GMAS tool, Oral anticancer drugs
Background: Medication adherence is a challenging issue. Non-adherence has been found to be associated with increased healthcare costs. Pharmacological anticancer therapies are increasingly shifting to oral medications. Oral therapy is more convenient and easier to administer but various issues are related to oral anticancer therapy, the prominent one being adherence.
Methods: Single group, non-randomized, self-report study conducted from December, 2019 to February, 2020 in SKIMS Hospital, Kashmir. A novel medication adherence scale, General Medication Adherence Scale (GMAS) was used to assess the adherence.
Results: The study population consists of 58.7% males and 41.3% females. 54.7% patients were illiterate and 45.3% patients were literate. 13.3% patients received one drug, 14.7% two drugs, 40.0% three drugs, and 32.0% received more than three drugs. 13.3% patients had poor, 9.3% low, 42.7% partial, 12.0% good and 22.7% high adherence. In low income group, 6.7% patients had poor, 6.7% low, 13.3% partial, 26.7% good and 46.7% high adherence. Among middle income group, 10.0% patients had poor, 10.0% low, 53.3% partial, 10.0% good and 16.7% high adherence. In high income group, 20.0% patients had poor, 10.0% low, 46.7% partial, 6.7% good and 16.7% high adherence.
Conclusions: Most of the cancer patients were partially adherent to the prescribed medication. Various associated factors were gender, socio-economic status, literacy, and place of residence. Considerable variation in adherence was found in this study.
World Health Organization (2018). Cancer. Available at: https://www.who.int/news-room/fact-sheets/detail/ cancer. Accessed on 2 January 2020.
American Cancer society. (2019). Cancer facts and figures. Available at: https://www.cancer.org/content/ dam/cancer-org/research/cancer-facts-and-statistics/ annual-cancer-facts-and-figures/2019/cancer-facts-and-figures-2019.pdf. Accessed on 2 January 2020.
Dhillon PK, Mathur P, Nandakumar A, Fitzmaurice C, Kumar GA, Mehrotra R, et al. The burden of cancers and their variations across the states of India: The Global Burden of Disease Study 1990-2016. Lancet Oncol. 2018;19:1289-306.
Paolella GA, Boyd AD, Wirth SM, Cuellar S, Venepalli NK, Crawford SY. Adherence to oral anticancer medications: evolving interprofessional roles and pharmacist workforce considerations. Pharmacy. 2018;6(1):23.
Partridge AH, Avorn J, Wang PS, Winer EP. Adherence to therapy with oral antineoplastic agents. J Nat Cancer Instit. 2002;94(9):652-61.
World Health Organization, 2003. Adherence to long-term therapies: Evidence for action. Geneva: World Health Organization. Available at: http://apps.who.int/ medicinedocs/pdf/s4883e/s4883e.pdf. Accessed on 2 January 2020.
Foulon V, Schöffski P, Wolter P. Patient adherence to oral anticancer drugs: an emerging issue in modern oncology. Acta Clin Belg. 2011;66(2):85-96.
Naqvi AA, Hassali MA, Rizvi M, Zehra A, Iffat W, Haseeb A, Jamshed S. Development and validation of a novel General Medication Adherence Scale (GMAS) for chronic illness patients in Pakistan. Frontier Pharmacol. 2018;9:1124.
Rolnick SJ, Pawloski PA, Hedblom BD, Asche SE, Bruzek RJ. Patient characteristics associated with medication adherence. Clini Medi Res. 2013;11(2):54-65.
Puts MT, Tu HA, Tourangeau A, Howell D, Fitch M, Springall E, et al. Factors influencing adherence to cancer treatment in older adults with cancer: a systematic review. Ann Oncol. 2014;25(3):564-77.
Greer JA, Amoyal N, Nisotel L, Fishbein JN, MacDonald J, Stagl J, et al. A systematic review of adherence to oral antineoplastic therapies. Oncologist. 2016;21(3):354-76.
Barillet M, Prevost V, Joly F, Clarisse B. Oral antineoplastic agents: how do we care about adherence?. Br J Clini Pharmacol. 2015;80(6):1289-302.